Catalog No.
Product Name
Application
Product Information
Citations
-
17β-HSD Inhibitor
HSD17B13-IN-1 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM with estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-1 provides valuable insights into the biochemical pathways involved in fatty liver disease and serves as a potential therapeutic target for related conditions. -
17β-HSD Inhibitor
HSD17B13-IN-31 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is crucial in researching nonalcoholic fatty liver diseases (NAFLDs), particularly nonalcoholic steatohepatitis (NASH), by modulating lipid metabolism and inflammation. HSD17B13-IN-31 serves as a valuable tool for studying the role of HSD17B13 in liver-related disorders and therapeutic interventions. -
17β-HSD Inhibitor
HSD17B13-IN-42 targets hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) as a potent inhibitor, exhibiting an IC50 of less than 0.1 μM with estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it a valuable tool for researchers investigating metabolic disorders and liver pathologies. -
17β-HSD Inhibitor
HSD17B13-IN-16 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound has significant relevance in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-16 serves as a valuable tool for researchers investigating metabolic disorders and potential therapeutic interventions in liver diseases. -
17β-HSD Inhibitor
HSD17B13-IN-35 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM when estradiol is used as a substrate. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), by targeting metabolic pathways involved in lipid metabolism. Its effective inhibition of HSD17B13 makes it a valuable reagent for research into therapeutic strategies for liver-related disorders. -
17β-HSD Inhibitor
HSD17B13-IN-28 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its ability to modulate HSD17B13 activity makes it a valuable tool for exploring the metabolic mechanisms underpinning liver disorders and evaluating potential therapeutic strategies. -
17β-HSD Inhibitor
HSD17B13-IN-40 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM against estradiol substrates. This compound is significant for research related to nonalcoholic fatty liver diseases (NAFLD), particularly nonalcoholic steatohepatitis (NASH), as it may provide insights into the modulation of lipid metabolism and inflammatory pathways. The compound's inhibitory action on HSD17B13 highlights its potential utility in exploring therapeutic strategies for metabolic disorders. -
17β-HSD Inhibitor
HSD17B13-IN-30 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), due to its role in modulating steroid metabolism and fatty liver progression. HSD17B13-IN-30 facilitates research into therapeutic approaches for liver-related metabolic disorders. -
17β-HSD1 Inhibitor
17β-HSD1-IN-2 is a non-estrogenic, steroidal covalent irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting a Ki of 368 nM. This compound demonstrates potential for studying estrogen-dependent disorders, facilitating research into therapeutic strategies for conditions influenced by estrogen metabolism. Its selective inhibition of 17β-HSD1 offers valuable insights into the enzyme's role in various biological processes and disease states. -
17β-HSD Inhibitor
HSD17B13-IN-21 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its application in research could provide insight into the mechanisms underlying liver-related metabolic disorders. -
17β-HSD10 Inhibitor
ESC1002755 is a selective inhibitor of 17β-HSD10, exhibiting an IC50 of 19 nM and demonstrating non-competitive inhibition against the cofactor NADH. This compound shows minimal cytotoxicity in HEK293 cells at a concentration of 50 μM, making it a promising tool for studies related to Alzheimer’s disease and hormone-dependent cancers, including prostate, bone, and colorectal cancer. Research applications include exploring the enzymatic mechanisms and therapeutic interventions associated with these conditions. -
17β-HSD Inhibitor
HSD17B13-IN-23 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), particularly in relation to nonalcoholic steatohepatitis (NASH). Its capacity to modulate HSD17B13 activity makes it a valuable tool for investigating the biochemical pathways involved in hepatic lipid metabolism and related disorders. -
17β-HSD Inhibitor
HSD17B13-IN-18 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for Leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), particularly in the study of nonalcoholic steatohepatitis (NASH). HSD17B13-IN-18 facilitates research aimed at understanding and potentially therapeutically targeting metabolic disorders related to liver function. -
17β-HSD1 Inhibitor
3-Acetyl-7-Hydroxycoumarin is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). It exhibits significant biological activity, demonstrating 57% inhibition of 17β-HSD1 at a concentration of 6 μM. This compound is valuable for research applications focused on hormone-dependent diseases, including breast cancer and endometriosis. -
17β-HSD Inhibitor
HSD17B13-IN-36 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it valuable for research concerning metabolic disorders and liver health. Its selective inhibition of HSD17B13 may provide insights into therapeutic interventions for liver-related diseases. -
FXR/HSD17B13 Modulator
FXR/HSD17B13 modulator 1 is a potent modulator targeting the farnesoid X receptor (FXR) and hydroxysteroid dehydrogenase 17 beta 13 (HSD17B13). This compound demonstrates significant biological activity relevant to the study of metabolic dysfunction-associated steatohepatitis (MASH). Its modulation of these targets can provide insights into therapeutic strategies for liver-related metabolic disorders. -
17β-HSD1 Inhibitor
7-Coumaryl triflate is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), demonstrating an IC₅₀ of 360 nM and a Kᵢ of 173 nM. This compound selectively targets 17β-HSD2 while displaying no significant affinity for estrogen receptors ERα or ERβ. 7-Coumaryl triflate is valuable for research focused on hormone-dependent breast cancer and the modulation of estrogen metabolism. -
17β-HSD Inhibitor
4'-Hydroxyvalerophenone is a specific inhibitor of 17β-hydroxysteroid dehydrogenase (17β-HSD), exhibiting an IC50 value of 60.52 μM. This compound plays a significant role in steroid metabolism and can be utilized in various research applications related to hormonal regulation and steroid biosynthesis. Its inhibitory effects make it a valuable tool for studies investigating the role of 17β-HSD in physiological and pathological processes. -
17β-HSD5 Inhibitor
17β-HSD5 inhibitor 1 is a potent inhibitor of 17β-HSD5, demonstrating an IC50 of 2.9 nM in HEK-293 cells that overexpress human 17β-HSD5. This compound is primarily utilized in research applications related to steroid metabolism and is instrumental in studying the modulation of sex steroid biosynthesis. The selective inhibition of 17β-HSD5 can provide insights into its role in various hormonal disorders and therapeutic interventions. -
17β-HSD5 Inhibitor
17β-HSD5 inhibitor 2 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase 5 (17β-HSD5), demonstrating an IC50 value of 40 nM. This compound is valuable for research into steroid metabolism and androgen biosynthesis, with potential applications in studying conditions related to hormone regulation and prostate cancer. Its inhibitory action enables the exploration of therapeutic strategies targeting 17β-HSD5 in various biological contexts. -
Herbicide
Chlorsulfuron is a selective herbicide that inhibits the enzyme acetolactate synthase, effectively blocking the biosynthesis of the amino acids valine and isoleucine in plants. This inhibition leads to the cessation of growth, making Chlorsulfuron a potent agent for controlling various weed species. It is primarily utilized in agricultural research to study plant physiology and herbicide resistance mechanisms. -
Herbicide
Pyrazosulfuron-ethyl is an herbicide that functions as an inhibitor of acetolactate synthase, a key enzyme in the biosynthetic pathway of branched-chain amino acids. This compound effectively controls a broad spectrum of weed species, making it valuable in agricultural applications, particularly in cereal, soybean, and vegetable crop production. Its selective action allows for effective weed management while minimizing harm to cultivated plants. -
Herbicide
Mesosulfuron-methyl is a sulfonylurea herbicide that targets acetolactate synthase (ALS). It exhibits effective post-emergence activity against various grass weeds, particularly ryegrass and wild oat species (Avena spp.), making it valuable in agricultural research focused on weed management in wheat cultivation. -
Herbicide
Cloransulam-methyl is a triazolopyrimidine sulfonanilide herbicide that functions primarily through the inhibition of acetolactate synthase (ALS). This compound effectively targets and controls broadleaf weeds in soybean crops. Its reliable herbicidal activity makes it a valuable tool for research focused on weed management and agricultural practices. -
Herbicide Safener
Herbicide Safener-2 is a herbicide safener that functions by competitively binding to the active site of acetolactate synthase (ALS), similar to mefenpyr-diethyl. This compound is designed to mitigate herbicide-induced injury in crops by enhancing their protection against herbicides such as mesosulfuron-methyl. Its pharmacokinetic profile allows for effective crop safeguarding during herbicide application, making it valuable for agricultural research and development. -
Herbicide
Triafamone is a sulfonamide herbicide that acts by inhibiting the enzyme acetolactate synthase (ALS). This inhibition disrupts the biosynthesis of branched-chain amino acids, leading to the effective control of various weed species. It is applicable in both pre-emergence and post-emergence scenarios in paddy fields, making it a valuable tool in agricultural weed management research. -
Sulfonylurea Herbicide
Prosulfuron is a fluorinated sulfonylurea herbicide that primarily targets acetolactate synthase (ALS), inhibiting the biosynthesis of branched-chain amino acids such as valine, leucine, and isoleucine in plants. This mechanism effectively suppresses the growth of certain weed species. Due to its low toxicity to humans and mammals, prosulfuron is utilized in research focused on broadleaf weed control in agricultural practices, particularly in maize and sweet corn. Additionally, it may influence the balance of soil microbial communities in alkaline conditions, highlighting its potential environmental impact. -
Herbicide
Pyrimisulfan is a selective inhibitor of acetolactate synthase (ALS) and functions as a broad-spectrum herbicide. It effectively targets a diverse array of paddy weeds, including annual grasses, sedges, and broadleaf species, as well as sulfonylurea-resistant biotypes, providing both pre- and post-emergence control. With its long residual activity and excellent safety profile for rice, Pyrimisulfan is valuable for research focusing on herbicidal mechanisms and paddy weed management strategies. -
Herbicide
Primisulfuron-methyl is a selective herbicide that targets the acetolactate synthase (ALS) enzyme, inhibiting its activity. This compound exhibits effective control of annual bluegrass in Kentucky bluegrass turf. Its specific mode of action makes Primisulfuron-methyl suitable for agricultural and research applications focused on turf management and weed control strategies. -
Herbicide
(E)-Pyriminobac-methyl is an acetolactate synthase inhibitor that functions as a pyrimidinylbenzoate herbicide. It effectively inhibits the biosynthesis of branched-chain amino acids, resulting in potent herbicidal activity. This compound has demonstrated efficacy against invasive species such as Echinochloa crus-galli and Leptochloa chinensis, with activity levels significantly surpassing those of certain other herbicides. Its application is essential for research focused on herbicide development and weed management strategies. -
Herbicide
Tritosulfuron is a sulfonylurea herbicide that targets acetolactate synthase, inhibiting its activity. This compound exhibits broad-spectrum efficacy as a post-emergent herbicide, specifically effective against dicotyledonous plants. It is commonly applied in the cultivation of cereals, maize, and turf to manage undesirable vegetation. -
CHI3L1 Inhibitor
CHI3L1-IN-1 is a selective inhibitor of Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40, with an IC50 of 50 nM. This compound exhibits additional effects by inhibiting the hERG channel with an IC50 of 2.3 μM. CHI3L1-IN-1 is valuable for research applications focused on the roles of CHI3L1 in inflammation and cancer, offering insights into its potential as a biomarker and therapeutic target. -
Endogenous Metabolite
O-Nornuciferine is an aporphine-type alkaloid derived from lotus leaf that acts as a potent inhibitor of the hERG channel. This endogenous metabolite is significant in the study of cardiac ion channels and provides insights into drug-induced cardiac arrhythmias. Its biological activity makes it a valuable reagent in pharmacological research and safety assessments. -
CYP2D6 Inhibitor
Guanfu base A is a potent noncompetitive inhibitor of CYP2D6, with a Ki value of 1.20 μM in human liver microsomes and 0.37 μM for the recombinant form. This antiarrhythmic alkaloid, derived from Aconitum coreanum, also exhibits competitive inhibition of CYP2D in monkey and dog microsomes, with Ki values of 0.38 μM and 2.4 μM, respectively. In addition to its CYP2D6 inhibitory activity, Guanfu base A demonstrates the ability to inhibit HERG channel current, making it relevant for studies in drug metabolism and cardiac electrophysiology. -
Endogenous Metabolite
Minoxidil hydrochloride is an ATP-sensitive potassium (KATP) channel opener with significant vasodilatory properties. Its primary applications include use as a potent oral antihypertensive agent and in promoting hair growth. Additionally, Minoxidil hydrochloride exhibits inhibitory activity against soybean lipoxygenase, with an IC50 value of 20 μM, making it valuable for research in cardiovascular and dermatological studies. -
CYP2D6 Inhibitor
Guanfu base A hydrochloride is a selective inhibitor of the CYP2D6 enzyme, demonstrating significant potential in the management of arrhythmia-related disorders. This alkaloid exhibits inhibitory effects across various species, including humans, primates, and canines. Its ability to modulate CYP2D6 activity may provide valuable insights and therapeutic applications in pharmacology and toxicology research. -
Omeprazole Metabolite
4-Hydroxy omeprazole sulfide is a key metabolite of the proton pump inhibitor omeprazole, primarily involved in modifying gastric acid secretion. This compound serves as a valuable tool in pharmacokinetic and metabolic studies of omeprazole and its effects on gastric mucosa. Its biological activity is significant for understanding drug metabolism and potential drug interactions in gastrointestinal research. -
CYP2C9/CYP3A4 Inhibitor
AR-C141990 functions as a dual inhibitor of CYP2C9 and CYP3A4, exhibiting IC50 values of 16 μM for both enzymes. This compound is recognized for its significant bioactivity, particularly as it inhibits the monocarboxylate transporter MCT1 with a Ki value of 4.8 nM. AR-C141990 is employed in research applications focused on drug metabolism and pharmacokinetics, as well as studies investigating interactions between drugs and metabolic pathways. -
CYP1B1 Activator
17-HETE is a metabolite of arachidonic acid produced via cytochrome P-450 pathways, comprising the 17R-HETE and 17S-HETE enantiomers. It acts as an allosteric activator of cytochrome P450 1B1 and an ATPase inhibitor, thereby playing a significant role in the induction of cardiac hypertrophy. This compound is valuable for research in cardiovascular biology and cytochrome P450 enzyme activity. -
CYP1B1 Activator
17(S)-HETE is a metabolite of arachidonic acid produced via cytochrome P-450 pathways. This compound functions as an allosteric activator of cytochrome P450 1B1 and inhibits ATPase activity, which may contribute to the induction of cardiac hypertrophy. 17(S)-HETE is primarily utilized in research focusing on cardiovascular biology and cytochrome P450 enzyme functions. -
Endogenous Metabolite
Cotinine, a primary metabolite of nicotine, acts as an endogenous biomarker for tobacco exposure. This alkaloid exhibits vasodepressor activity and has demonstrated antiproliferative effects when combined with nicotine against conditions such as pterygium. Additionally, (S)-(-)-Cotinine activates nicotinic acetylcholine receptors (nAChR) in a calcium-dependent manner, facilitating dopamine release. Due to its diverse biological activities, cotinine is employed in research focused on cardiovascular and inflammatory diseases. -
11β-HSD2 Inhibitor
18β-Glycyrrhetyl-3-O-sulfate is a potent inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), exhibiting an IC50 value of 0.10 µM in rat kidney microsomes. As the principal metabolite of Glycyrrhetinic acid, this compound serves as a substrate for organic anion transporters OAT1 and OAT3. Its anti-inflammatory properties make it a valuable tool for studying pseudohyperaldosteronism and related conditions in biochemical and pharmacological research. -
Endogenous Metabolite
Estradiol 3-sulfate 17-glucuronide potassium is an endogenous metabolite derived from estradiol, specifically targeting the multidrug resistance protein (MRP). It is known to inhibit MRP-mediated transport of 17β-Estradiol 17-(β-D-Glucuronide) with an inhibition constant (Ki) of 22 μM. This compound is useful in studying the pharmacokinetics of estrogenic compounds and understanding their role in hormone metabolism and transport mechanisms. -
CRM1 Degrader
CRM1 Degrader 1 is a targeted agent that selectively degrades chromosome region maintenance 1 (CRM1), a nuclear exporter critical for the transport of various tumor suppressor proteins. By inducing apoptosis in gastric carcinoma cells, CRM1 Degrader 1 demonstrates significant anti-proliferative effects, making it a valuable tool for cancer research. This compound is primarily used to explore therapeutic strategies aimed at regulating CRM1-related pathways in cancer biology. -
Endogenous Metabolite
Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine that serves as a modulator of glycine transport. It exhibits inhibitory activity on the GlyT2 receptor, reducing glycine responses by 16.8% at concentrations up to 3 μM. This compound is of interest in research focusing on neurotransmitter regulation and metabolic processes related to acylcarnitines. -
Endogenous Metabolite
24(S)-Hydroxycholesterol (24S-OHC) is an endogenous metabolite primarily involved in cholesterol homeostasis within the brain. As a potent and selective positive allosteric modulator of N-methyl-D-aspartate receptors (NMDARs), 24S-OHC functions through a unique mechanism distinct from other allosteric modulators. Its high levels in both the brain and circulation make it a valuable tool for research into neurological functions and disorders related to cholesterol metabolism and synaptic transmission. -
Acetylcholinesterase Inhibitor, Butyrylcholinesterase Inhibitor, Carbonic Anhydrase I/II Inhibitor, α-Glycosidase Inhibitor
Vescalagin is a hexahydroxyphenol that acts as an inhibitor of acetylcholinesterase and butyrylcholinesterase, as well as carbonic anhydrases I and II, and α-glycosidase. It demonstrates potent inhibitory activity with Ki values of 5.87 nM for AChE, 3.89 nM for BChE, 11.75 nM for hCA I, 16.23 nM for hCA II, and 16.08 nM for α-glycosidase. Vescalagin exhibits non-competitive inhibition for hCA I, hCA II, and α-glycosidase, while also reducing hyperglycemia and hypertriglyceridemia in dietary models. Additionally, it possesses anti-inflammatory and antioxidant activities, making it a valuable compound for research in diabetes and metabolic disorders. -
Endogenous Metabolite
3-Hydroxyisobutyric acid sodium is an endogenous metabolite involved in the metabolic pathways of L-valine and thymine. It serves as a mediator in endothelial cell fatty acid transport and has implications in insulin resistance. Additionally, this compound can inhibit key enzymes involved in energy metabolism in the cerebral cortex of young rats. Elevated levels of 3-Hydroxyisobutyric acid sodium are associated with conditions such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis, making it a significant target for research on metabolic disorders. -
Stable Isotope
Verapamil-d3 hydrochloride is a deuterium-labeled derivative of the calcium channel blocker, verapamil hydrochloride. It serves as a potent inhibitor of P-glycoprotein (P-gp) and CYP3A4, facilitating detailed pharmacological studies. This stable isotope is primarily utilized in research related to hypertension, cardiac arrhythmias, and angina, providing insight into drug metabolism and transport mechanisms in various biological systems. -
IDO1 Inhibitor
IDO1-IN-19 is a selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 value of 8.64 μM for CYP2C9. In addition, it modulates cardiac ion channels with IC50 values of 12 μM for IKr, 40 μM for INa, and 8.3 μM for ICa. This compound is valuable for investigating the mechanisms of cancer biology and has potential applications in cancer therapeutics.
